查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1322219

腫瘤血液學分子檢測市場 - 全球行業分析、規模、佔有率、成長、趨勢和預測，2023-2031年

Onco-hematology Molecular Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 179 Pages | 商品交期: 2-10個工作天內

價格

腫瘤血液學分子檢測市場 - 報告範圍

TMR的全球腫瘤血液學分子檢測市場的報告研究了過去以及當前的成長趨勢和機會，以獲得2023年至2031年預測期內市場指標的寶貴見解。本報告提供了全球2017-2031年期間腫瘤血液學分子檢測市場的收入，以2023年為基準年，2031年為預測年。本報告還提供了2023年至2031年全球腫瘤血液學分子檢測市場的年複合成長率（CAGR%）。

本報告是經過廣泛研究後編寫的。初級研究包括大部分研究工作，其中分析師對關鍵意見領袖、行業領袖和輿論製造者進行了採訪。二次研究包括參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解腫瘤血液學分子檢測市場。

本報告深入研究了全球腫瘤血液學分子檢測市場的競爭格局。全球腫瘤血液學分子檢測市場的主要參與者已經確定，並且每一位參與者都已根據各種屬性進行了分析。公司概述、財務狀況、最新發展和 SWOT 是本報告中介紹的全球腫瘤血液學分子檢測市場參與者的屬性。

目錄

第1章：前言

第2章：假設和研究方法

第3章：執行摘要：全球市場

第4章：市場概述

  • 介紹
  • 概述
  • 市場動態
  • 2017-2031年全球市場分析與預測

第5章：關鍵見解

  • 市場概況
  • 主要產品/品牌分析
  • 管道分析
  • COVID-19 大流行對行業的影響

第6章：全球市場分析與預測：按血癌類型

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按血癌類型，2017-2031
    • 慢性骨髓性白血病
      • 真性紅血球增多症
      • 原發性血小板增多症
      • 骨髓纖維化
    • 骨髓增生性腫瘤
    • 急性骨髓性白血病
    • 急性淋巴母細胞白血病
  • 市場吸引力分析：按血癌類型

第7章：全球市場分析與預測：按血癌生物標記分類

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按血癌生物標記分類，2017-2031
    • BCR-ABL1 MBCR
    • JAK2
    • CALR
    • MPL
    • PML-RARA
    • NPM1
    • RUNX1-RUNX1T1
    • CBFB-MYH11
    • BCR-ABL1 mbcr
  • 市場吸引力分析：按血癌生物標記

第8章：全球市場分析與預測：按技術分類

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按技術分類，2017-2031
    • 定量PCR
    • 聚合酶鍊式反應
    • 下一代測序
    • 其他
  • 市場吸引力分析：按技術分類

第9章：全球市場分析與預測：按最終用戶

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按最終用戶，2017-2031
    • 國家參考實驗室/專業實驗室
    • 大學醫院/腫瘤中心
    • 社區醫院/IDN（地區/國家
  • 市場吸引力分析：按最終用戶

第10章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2017-2031
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第11章：北美市場分析與預測

第12章：歐洲市場分析與預測

第13章：亞太市場分析與預測

第14章：拉丁美洲市場分析與預測

第15章：中東和非洲市場分析與預測

第16章：競爭格局

  • 市場參與者 - 競爭矩陣（按公司層級和規模）
  • 市場佔有率分析：按公司分類，2022年
  • 公司簡介
    • Asuragen, Inc.
    • Bio-Rad Laboratories, Inc.
    • ICON plc
    • Integrated DNA Technologies, Inc. (ArcherDx, Inc.)
    • Invivoscribe, Inc.
    • QIAGEN NV
    • Thermo Fisher Scientific, Inc.
    • Cepheid
    • Illumina, Inc.
Product Code: TMRGL85642

Onco-hematology Molecular Testing Market - Scope of Report

TMR's report on the global Onco-hematology Molecular Testing Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Onco-hematology Molecular Testing Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Onco-hematology Molecular Testing Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Onco-hematology Molecular Testing Market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Onco-hematology Molecular Testing Market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Onco-hematology Molecular Testing Market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Onco-hematology Molecular Testing Market.

The report delves into the competitive landscape of the global Onco-hematology Molecular Testing Market. Key players operating in the global Onco-hematology Molecular Testing Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Onco-hematology Molecular Testing Market profiled in this report.

Key Questions Answered in Global Onco-hematology Molecular Testing Market Report:

  • What is the sales/revenue generated by mobile photo printer across all regions during the forecast period?
  • What are the opportunities in the global Onco-hematology Molecular Testing Market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Onco-hematology Molecular Testing Market - Research Objectives and Research Approach

The comprehensive report on the global Onco-hematology Molecular Testing Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Onco-hematology Molecular Testing Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Onco-hematology Molecular Testing .

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Onco-hematology Molecular Testing Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Onco-hematology Molecular Testing Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Overview of Onco-hematology Molecular Testing Market
  • 5.2. Key Product/ Brand Analysis
  • 5.3. Pipeline Analysis
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Blood Cancer Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Blood Cancer Type, 2017-2031
    • 6.3.1. Chronic Myeloid Leukemia
      • 6.3.1.1. Polycythemia Vera
      • 6.3.1.2. Essential Thrombocythaemia
      • 6.3.1.3. Myelofibrosis
    • 6.3.2. Myeloproliferative Neoplasms
    • 6.3.3. Acute Myeloid Leukemia
    • 6.3.4. Acute Lymphoblastic Leukemia
  • 6.4. Market Attractiveness Analysis, by Blood Cancer Type

7. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Blood Cancer Biomarker

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
    • 7.3.1. BCR-ABL1 MBCR
    • 7.3.2. JAK2
    • 7.3.3. CALR
    • 7.3.4. MPL
    • 7.3.5. PML-RARA
    • 7.3.6. NPM1
    • 7.3.7. RUNX1-RUNX1T1
    • 7.3.8. CBFB-MYH11
    • 7.3.9. BCR-ABL1 mbcr
  • 7.4. Market Attractiveness Analysis, by Blood Cancer Biomarker

8. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Technology

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Technology, 2017-2031
    • 8.3.1. qPCR
    • 8.3.2. dPCR
    • 8.3.3. Next-Generation Sequencing
    • 8.3.4. Others
  • 8.4. Market Attractiveness Analysis, by Technology

9. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by End-user, 2017-2031
    • 9.3.1. National Reference Lab/Specialty Lab
    • 9.3.2. University Hospital/Oncology Center
    • 9.3.3. Community Hospital/IDN (Regional/National
  • 9.4. Market Attractiveness Analysis, by End-user

10. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2017-2031
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness Analysis, by Region

11. North America Onco-hematology Molecular Testing Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
    • 11.2.1. Chronic Myeloid Leukemia
      • 11.2.1.1. Polycythemia Vera
      • 11.2.1.2. Essential Thrombocythaemia
      • 11.2.1.3. Myelofibrosis
    • 11.2.2. Myeloproliferative Neoplasms
    • 11.2.3. Acute Myeloid Leukemia
    • 11.2.4. Acute Lymphoblastic Leukemia
  • 11.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
    • 11.3.1. BCR-ABL1 MBCR
    • 11.3.2. JAK2
    • 11.3.3. CALR
    • 11.3.4. MPL
    • 11.3.5. PML-RARA
    • 11.3.6. NPM1
    • 11.3.7. RUNX1-RUNX1T1
    • 11.3.8. CBFB-MYH11
    • 11.3.9. BCR-ABL1 mbcr
  • 11.4. Market Value Forecast, by Technology, 2017-2031
    • 11.4.1. qPCR
    • 11.4.2. dPCR
    • 11.4.3. Next-Generation Sequencing
    • 11.4.4. Others
  • 11.5. Market Value Forecast, by End-user, 2017-2031
    • 11.5.1. National Reference Lab/Specialty Lab
    • 11.5.2. University Hospital/Oncology Center
    • 11.5.3. Community Hospital/IDN (Regional/National
  • 11.6. Market Value Forecast, by Country, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Blood Cancer Type
    • 11.7.2. By Blood Cancer Biomarker
    • 11.7.3. By Technology
    • 11.7.4. By End-user
    • 11.7.5. By Country

12. Europe Onco-hematology Molecular Testing Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
    • 12.2.1. Chronic Myeloid Leukemia
      • 12.2.1.1. Polycythemia Vera
      • 12.2.1.2. Essential Thrombocythaemia
      • 12.2.1.3. Myelofibrosis
    • 12.2.2. Myeloproliferative Neoplasms
    • 12.2.3. Acute Myeloid Leukemia
    • 12.2.4. Acute Lymphoblastic Leukemia
  • 12.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
    • 12.3.1. BCR-ABL1 MBCR
    • 12.3.2. JAK2
    • 12.3.3. CALR
    • 12.3.4. MPL
    • 12.3.5. PML-RARA
    • 12.3.6. NPM1
    • 12.3.7. RUNX1-RUNX1T1
    • 12.3.8. CBFB-MYH11
    • 12.3.9. BCR-ABL1 mbcr
  • 12.4. Market Value Forecast, by Technology, 2017-2031
    • 12.4.1. qPCR
    • 12.4.2. dPCR
    • 12.4.3. Next-Generation Sequencing
    • 12.4.4. Others
  • 12.5. Market Value Forecast, by End-user, 2017-2031
    • 12.5.1. National Reference Lab/Specialty Lab
    • 12.5.2. University Hospital/Oncology Center
    • 12.5.3. Community Hospital/IDN (Regional/National
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Blood Cancer Type
    • 12.7.2. By Blood Cancer Biomarker
    • 12.7.3. By Technology
    • 12.7.4. By End-user
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Onco-hematology Molecular Testing Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
    • 13.2.1. Chronic Myeloid Leukemia
      • 13.2.1.1. Polycythemia Vera
      • 13.2.1.2. Essential Thrombocythaemia
      • 13.2.1.3. Myelofibrosis
    • 13.2.2. Myeloproliferative Neoplasms
    • 13.2.3. Acute Myeloid Leukemia
    • 13.2.4. Acute Lymphoblastic Leukemia
  • 13.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
    • 13.3.1. BCR-ABL1 MBCR
    • 13.3.2. JAK2
    • 13.3.3. CALR
    • 13.3.4. MPL
    • 13.3.5. PML-RARA
    • 13.3.6. NPM1
    • 13.3.7. RUNX1-RUNX1T1
    • 13.3.8. CBFB-MYH11
    • 13.3.9. BCR-ABL1 mbcr
  • 13.4. Market Value Forecast, by Technology, 2017-2031
    • 13.4.1. qPCR
    • 13.4.2. dPCR
    • 13.4.3. Next-Generation Sequencing
    • 13.4.4. Others
  • 13.5. Market Value Forecast, by End-user, 2017-2031
    • 13.5.1. National Reference Lab/Specialty Lab
    • 13.5.2. University Hospital/Oncology Center
    • 13.5.3. Community Hospital/IDN (Regional/National
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Blood Cancer Type
    • 13.7.2. By Blood Cancer Biomarker
    • 13.7.3. By Technology
    • 13.7.4. By End-user
    • 13.7.5. By Country/Sub-region

14. Latin America Onco-hematology Molecular Testing Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
    • 14.2.1. Chronic Myeloid Leukemia
      • 14.2.1.1. Polycythemia Vera
      • 14.2.1.2. Essential Thrombocythaemia
      • 14.2.1.3. Myelofibrosis
    • 14.2.2. Myeloproliferative Neoplasms
    • 14.2.3. Acute Myeloid Leukemia
    • 14.2.4. Acute Lymphoblastic Leukemia
  • 14.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
    • 14.3.1. BCR-ABL1 MBCR
    • 14.3.2. JAK2
    • 14.3.3. CALR
    • 14.3.4. MPL
    • 14.3.5. PML-RARA
    • 14.3.6. NPM1
    • 14.3.7. RUNX1-RUNX1T1
    • 14.3.8. CBFB-MYH11
    • 14.3.9. BCR-ABL1 mbcr
  • 14.4. Market Value Forecast, by Technology, 2017-2031
    • 14.4.1. qPCR
    • 14.4.2. dPCR
    • 14.4.3. Next-Generation Sequencing
    • 14.4.4. Others
  • 14.5. Market Value Forecast, by End-user, 2017-2031
    • 14.5.1. National Reference Lab/Specialty Lab
    • 14.5.2. University Hospital/Oncology Center
    • 14.5.3. Community Hospital/IDN (Regional/National
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Blood Cancer Type
    • 14.7.2. By Blood Cancer Biomarker
    • 14.7.3. By Technology
    • 14.7.4. By End-user
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Onco-hematology Molecular Testing Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
    • 15.2.1. Chronic Myeloid Leukemia
      • 15.2.1.1. Polycythemia Vera
      • 15.2.1.2. Essential Thrombocythaemia
      • 15.2.1.3. Myelofibrosis
    • 15.2.2. Myeloproliferative Neoplasms
    • 15.2.3. Acute Myeloid Leukemia
    • 15.2.4. Acute Lymphoblastic Leukemia
  • 15.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
    • 15.3.1. BCR-ABL1 MBCR
    • 15.3.2. JAK2
    • 15.3.3. CALR
    • 15.3.4. MPL
    • 15.3.5. PML-RARA
    • 15.3.6. NPM1
    • 15.3.7. RUNX1-RUNX1T1
    • 15.3.8. CBFB-MYH11
    • 15.3.9. BCR-ABL1 mbcr
  • 15.4. Market Value Forecast, by Technology, 2017-2031
    • 15.4.1. qPCR
    • 15.4.2. dPCR
    • 15.4.3. Next-Generation Sequencing
    • 15.4.4. Others
  • 15.5. Market Value Forecast, by End-user, 2017-2031
    • 15.5.1. National Reference Lab/Specialty Lab
    • 15.5.2. University Hospital/Oncology Center
    • 15.5.3. Community Hospital/IDN (Regional/National
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Blood Cancer Type
    • 15.7.2. By Blood Cancer Biomarker
    • 15.7.3. By Technology
    • 15.7.4. By End-user
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (by tier and size of companies)
  • 16.2. Market Share Analysis, by Company, 2022
  • 16.3. Company Profiles
    • 16.3.1. Asuragen, Inc.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Bio-Rad Laboratories, Inc.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. ICON plc
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Integrated DNA Technologies, Inc. (ArcherDx, Inc.)
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Invivoscribe, Inc.
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. QIAGEN N.V.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Thermo Fisher Scientific, Inc.
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Cepheid
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Illumina, Inc.
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview

List of Tables

  • Table 01: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
  • Table 02: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017-2031
  • Table 03: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 04: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 05: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
  • Table 08: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017-2031
  • Table 09: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 10: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 11: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 12: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
  • Table 13: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017-2031
  • Table 14: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 15: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 16: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
  • Table 18: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017-2031
  • Table 19: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 20: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 21: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
  • Table 23: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017-2031
  • Table 24: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 25: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 26: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 27: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Type, 2017-2031
  • Table 28: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Blood Cancer Biomarker, 2017-2031
  • Table 29: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 30: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Onco-hematology Molecular Testing Market Value Share, by Blood Cancer Type, 2022
  • Figure 03: Global Onco-hematology Molecular Testing Market Value Share, by Blood Cancer Biomarker, 2022
  • Figure 04: Global Onco-hematology Molecular Testing Market Value Share, by Technology, 2022
  • Figure 05: Global Onco-hematology Molecular Testing Market Value Share, by End-user, 2022
  • Figure 06: Global Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Type, 2022 and 2031
  • Figure 07: Global Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Type, 2023-2031
  • Figure 08: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by Chronic Myeloid Leukemia , 2017-2031
  • Figure 09: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by Myeloproliferative Neoplasms, 2017-2031
  • Figure 10: Global Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Biomarker, 2022 and 2031
  • Figure 11: Global Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Biomarker 2023-2031
  • Figure 12: Global Onco-hematology Molecular Testing Market Value (US$ Mn), by BCR-ABL1 MBCR, 2017-2031
  • Figure 13: Global Onco-hematology Molecular Testing Market Value (US$ Mn), by JAK2, 2017-2031
  • Figure 14: Global Onco-hematology Molecular Testing Market Value (US$ Mn), by Irreversible CALR, 2017-2031
  • Figure 15: Global Onco-hematology Molecular Testing Market Value (US$ Mn), by MPL, 2017-2031
  • Figure 16: Global Onco-hematology Molecular Testing Market Value (US$ Mn), by Others, 2017-2031
  • Figure 17: Global Onco-hematology Molecular Testing Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 18: Global Onco-hematology Molecular Testing Market Attractiveness Analysis, Technology, 2023-2031
  • Figure 19: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by QPCR , 2017-2031
  • Figure 20: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by DPCR, 2017-2031
  • Figure 21: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by Next-Generation Sequencing, 2017-2031
  • Figure 22: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 23: Global Onco-hematology Molecular Testing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 24: Global Onco-hematology Molecular Testing Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 25: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by National Reference Lab/Specialty Lab, 2017-2031
  • Figure 26: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by University Hospital/Oncology Center, 2017-2031
  • Figure 27: Global Onco-hematology Molecular Testing Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 28: Global Onco-hematology Molecular Testing Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 29: Global Onco-hematology Molecular Testing Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 30: North America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 31: North America Onco-hematology Molecular Testing Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 32: North America Onco-hematology Molecular Testing Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 33: North America Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Type, 2022 and 2031
  • Figure 34: North America Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Type, 2023-2031
  • Figure 35: North America Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Biomarker, 2022 and 2031
  • Figure 36: North America Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Biomarker 2023-2031
  • Figure 37: North America Onco-hematology Molecular Testing Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 38: North America Onco-hematology Molecular Testing Market Attractiveness Analysis, Technology, 2023-2031
  • Figure 39: North America Onco-hematology Molecular Testing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 40: North America Onco-hematology Molecular Testing Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 41: Europe Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 42: Europe Onco-hematology Molecular Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 43: Europe Onco-hematology Molecular Testing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 44: Europe Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Type, 2022 and 2031
  • Figure 45: Europe Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Type, 2023-2031
  • Figure 46: Europe Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Biomarker, 2022 and 2031
  • Figure 47: Europe Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Biomarker 2023-2031
  • Figure 48: Europe Onco-hematology Molecular Testing Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 49: Europe Onco-hematology Molecular Testing Market Attractiveness Analysis, Technology, 2023-2031
  • Figure 50: Europe Onco-hematology Molecular Testing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 51: Europe Onco-hematology Molecular Testing Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 52: Asia Pacific Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 53: Asia Pacific Onco-hematology Molecular Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 54: Asia Pacific Onco-hematology Molecular Testing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 55: Asia Pacific Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Type, 2022 and 2031
  • Figure 56: Asia Pacific Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Type, 2023-2031
  • Figure 57: Asia Pacific Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Biomarker, 2022 and 2031
  • Figure 58: Asia Pacific Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Biomarker 2023-2031
  • Figure 59: Asia Pacific Onco-hematology Molecular Testing Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 60: Asia Pacific Onco-hematology Molecular Testing Market Attractiveness Analysis, Technology, 2023-2031
  • Figure 61: Asia Pacific Onco-hematology Molecular Testing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 62: Asia Pacific Onco-hematology Molecular Testing Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 63: Latin America Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 64: Latin America Onco-hematology Molecular Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 65: Latin America Onco-hematology Molecular Testing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 66: Latin America Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Type, 2022 and 2031
  • Figure 67: Latin America Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Type, 2023-2031
  • Figure 68: Latin America Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Biomarker, 2022 and 2031
  • Figure 69: Latin America Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Biomarker, 2023-2031
  • Figure 70: Latin America Onco-hematology Molecular Testing Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 71: Latin America Onco-hematology Molecular Testing Market Attractiveness Analysis, Technology, 2023-2031
  • Figure 72: Latin America Onco-hematology Molecular Testing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 73: Latin America Onco-hematology Molecular Testing Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 74: Middle East & Africa Onco-hematology Molecular Testing Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 75: Middle East & Africa Onco-hematology Molecular Testing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 76: Middle East & Africa Onco-hematology Molecular Testing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 77: Middle East & Africa Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Type, 2022 and 2031
  • Figure 78: Middle East & Africa Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Type, 2023-2031
  • Figure 79: Middle East & Africa Onco-hematology Molecular Testing Market Value Share Analysis, by Blood Cancer Biomarker, 2022 and 2031
  • Figure 80: Middle East & Africa Onco-hematology Molecular Testing Market Attractiveness Analysis, by Blood Cancer Biomarker 2023-2031
  • Figure 81: Middle East & Africa Onco-hematology Molecular Testing Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 82: Middle East & Africa Onco-hematology Molecular Testing Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 83: Middle East & Africa Onco-hematology Molecular Testing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 84: Middle East & Africa Onco-hematology Molecular Testing Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 85: Global Onco-hematology Molecular Testing Market Share Analysis, by Company (2022)